P. Papanastasiou, Greece
ELPEN Pharmaceutical Co. Inc. Medical DepartmentPresenter of 1 Presentation
O049 - Evaluation of depression and anxiety control in Greek patients with major depressive disorder with/without generalized anxiety disorder and Cardiovascular Disease–PRONOI study
ABSTRACT
Introduction
Patients with depression are likely to eventually develop Cardiovascular disease(CVD) and have a higher mortality rate than general population. In addition, anxiety disorders, especially Generalized Anxiety Disorder(GAD), may be associated with mortality and other adverse cardiac outcomes.
Objectives
Evaluation of depression and anxiety control in Greek patients with Major Depressive Disorder(MDD) with/without GAD and CVD, under 6 months of treatment with citalopram, and/or quetiapine, and/or pregabalin.
Methods
565 patients with MDD with/without GAD, enrolled in this observational, study(NCT03317262). The subgroup of 133(24%) patients had CVD. Severity of MDD and GAD symptoms was evaluated using the HAM-D and HAM-A Scores at baseline(V1) and after 6 months(V3) respectively.
Results
Mean HAM-D score in patients with CVD without GAD, at V1 and V3 was 23.94±7.51 and 8.14±4.65 respectively (p<0.0001). Similar results were observed in patients without CVD without GAD (HAM-D score 26.67±8.79 at V1 and 7.44±4.40 at V3). Mean HAM-A score in patients with CVD and GAD at V1 and V3 was 25.64±6.38 and 8.98±3.93, respectively (p<0.0001). Same magnitude reduction in HAM-A score was observed in patients without CVD and GAD, 26.27±8.16 at V1 and 9.28±6.48 at V3 (p<0.0001). Patients’ depression symptoms with/without CVD and GAD showed also a significant reduction between V1 and V3.
Conclusions
MDD patients with CVD without GAD, had a marginally lower baseline HAM-D score versus patients with GAD. After 6 months of treatment with citalopram, and/or quetiapine, and/or pregabalin the improvement of depressive and anxiety symptoms was almost equal between MDD patients with/without GAD regardless of the presence of coexisting CVD.